Clinical Trials & Pipeline
Clinical Trials & Pipeline
Millions of people worldwide are living with unmet health needs. At Bayer, our focus is to discover and develop medicines that provide the opportunity to live a healthier life. We are actively pursuing our vision to deliver best-in-class patient care, outcomes, and experience by advancing science.
Information on investigational compounds and clinical trials sponsored by Bayer is being shared to increase the transparency of Bayer's clinical research. Research sponsored by independent investigators is not included.
Ongoing Trials
Risk Score To Determine Prophylaxis Dosing Regimens
PREDICT Phase IV Study
A study to assess a new scoring system based on the best known phenotypic and biologic variables to select the most appropriate regimen for patients with hemophilia A switching from standard-half-life recombinant factor VIII to damoctocog alfa pegol
HEM-POWR Phase IV Study
A study to evaluate the effectiveness and long-term safety of damoctocog alfa pegol in previously treated patients with mild, moderate, and severe hemophilia A in a real-world clinical setting
Real World Prospective Phase IV Study
PTPs 7 to <12 Prospective Phase III Study
Alfa-PROTECT Phase III Study
A study to evaluate the safety of damoctocog alfa pegol in previously treated children aged 7 to less than 12 years with severe hemophilia A
Follow Us
